Bcl-2 and Interferon in Renal Cancer Treatment
Author Information
Author(s): Kelly J D, Dai J, Eschwege P, Goldberg J S, Duggan B P, Williamson K E, Bander N H, Nanus D M
Primary Institution: Department of Oncology, Cambridge University
Hypothesis
Resistance to IFNα may be overcome by G3193, an antisense oligonucleotide targeting Bcl-2.
Conclusion
G3139 in combination with IFNα may be a potential therapy for patients with metastatic renal cell carcinoma.
Supporting Evidence
- IFNα induced Fas and Bcl-2 in renal cancer cell lines.
- G3139 downregulated Bcl-2, sensitizing resistant cells to anti-Fas.
- PARP cleavage was observed in sensitive cell lines after treatment.
Takeaway
Researchers found that a drug called G3139 can help make kidney cancer cells more sensitive to a treatment called interferon, which can help kill the cancer cells.
Methodology
Human renal cancer cell lines were treated with interferon α and G3139, followed by analysis of cell viability and apoptosis.
Limitations
The study was conducted in vitro, and results may not fully translate to in vivo conditions.
Statistical Information
P-Value
p<0.003
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website